Saturday 17 October 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024. In the quarter to June 2026, revenue grew 32.5%, EPS fell 34.2%, free cash flow fell 68.6% and total debt rose 1.52%, each against the same quarter a year earlier.
25.04
2.60
−9.41%
Follow CBLL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 23.00 | 10.01 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 32.75 | 26.83 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 240 | 281 | 327 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.19 | 0.23 | 0.27 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 45 | 65 | 89 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 84.38 | 86.72 | 87.89 | |||||
| EBT | — | — | — | — | — | — | — | (29) | (40) | (53) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (65.13) | (61.82) | (59.97) | |||||
| Net income | — | — | — | — | — | — | — | (29) | (40) | (53) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 2 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 8.53 | 5.48 | 2.44 | ||||
| Earnings | — | — | — | — | — | — | — | (5.56) | (3.39) | (1.46) | |||||
| Cash flow | — | — | — | — | — | — | — | (5.50) | (2.93) | (1.12) | |||||
| Capex | — | — | — | — | — | — | — | (0.33) | (0.13) | (0.04) | |||||
| Free cash flow | — | — | — | — | — | — | — | (5.83) | (3.07) | (1.16) | |||||
| Book value | — | — | — | — | — | — | — | (21.16) | 16.00 | 4.25 | |||||
| Shares, m | — | — | — | — | — | — | — | 5 | 12 | 37 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 2.41 | 4.73 | 9.00 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 1.62 | 5.16 | |||||
| EV/Sales | — | — | — | — | — | — | — | 2.50 | 2.05 | 7.43 | |||||
| EV/FCF | — | — | — | — | — | — | — | (4.47) | (3.67) | (15.64) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (29) | (35) | (41) | ||||
| Capex | — | — | — | — | — | — | — | (2) | (2) | (2) | |||||
| Free cash flow | — | — | — | — | — | — | — | (31) | (37) | (42) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 30 | 204 | 168 | ||||
| Total debt | — | — | — | — | — | — | — | — | 20 | 20 | |||||
| Net debt | — | — | — | — | — | — | — | (34) | (175) | (139) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (112) | 191 | 155 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (28.46) | (25.36) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (151.76) | (229.77) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (102.53) | (30.83) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
CeriBell, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BVS Bioventus Inc. | $1.2B | 16.4× | 21.4× | +3.76% (above 0%: growing) | +345.45% (above 0%: growing) | −25.11% (below 0%: shrinking) | 68.97% | 12.48% | Compare |
| TNDM Tandem Diabetes Care, Inc. | $1.2B | — (loss-making) | — (loss-making) | +5.77% (above 0%: growing) | n/m | −146.34% (below 0%: shrinking) | 56.87% | (5.42%) | Compare |
| IRMD iRadimed Corporation | $1.1B | 48.5× | 48.7× | +0.28% (above 0%: growing) | −8.89% (below 0%: shrinking) | +11.66% (above 0%: growing) | 74.07% | 31.23% | Compare |
| ENOV Enovis Corporation | $1.1B | — (loss-making) | 195× | +3.23% (above 0%: growing) | n/m | +815.79% (above 0%: growing) | 61.64% | 2.99% | Compare |
| AORT Artivion, Inc. | $1.1B | — (loss-making) | 142× | +11.32% (above 0%: growing) | n/m | −202.47% (below 0%: shrinking) | 64.03% | (6.65%) | Compare |
| CBLL CeriBell, Inc. | $1.1B | — (loss-making) | — (loss-making) | +32.54% (above 0%: growing) | n/m | −68.63% (below 0%: shrinking) | 92.32% | (71.11%) | |
| IART Integra LifeSciences Holdings Corporation | $1.1B | — (loss-making) | 26.1× | +0.76% (above 0%: growing) | n/m | +193.48% (above 0%: growing) | 52.47% | 4.61% | Compare |
| LMRI Lumexa Imaging Holdings, Inc. | $1.0B | — (loss-making) | 14.2× | +7.82% (above 0%: growing) | n/m | +257.54% (above 0%: growing) | 14.72% | 8.72% | Compare |
| PRCT PROCEPT BioRobotics Corporation | $1.0B | — (loss-making) | — (loss-making) | +19.34% (above 0%: growing) | n/m | −24.43% (below 0%: shrinking) | 66.01% | (28.98%) | Compare |
| Median of peers | $1.1B | — | 37.4× | +4.77% | — | −6.38% | 62.84% | 3.80% |
CeriBell, Inc. (CBLL) key facts
- Strength: CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024.
- CeriBell, Inc. (CBLL) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CBLL traded at $25.04, a market capitalization of $1.1 billion.
- Return on equity was −30.8% and debt-to-equity 0.16.
- Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 10.80 (safe zone) for fiscal 2025.
CeriBell, Inc. (CBLL) Latest News
No news at this impact. Lower the threshold for more.